These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 35892906)
1. Clinical Characteristics, Genetic Findings and Arrhythmic Outcomes of Patients with Catecholaminergic Polymorphic Ventricular Tachycardia from China: A Systematic Review. Leung J; Lee S; Zhou J; Jeevaratnam K; Lakhani I; Radford D; Coakley-Youngs E; Pay L; Çinier G; Altinsoy M; Behnoush AH; Mahmoudi E; Matusik PT; Bazoukis G; Garcia-Zamora S; Zeng S; Chen Z; Xia Y; Liu T; Tse G Life (Basel); 2022 Jul; 12(8):. PubMed ID: 35892906 [TBL] [Abstract][Full Text] [Related]
2. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588 [TBL] [Abstract][Full Text] [Related]
3. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report. Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944 [TBL] [Abstract][Full Text] [Related]
4. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature. Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648 [TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101 [TBL] [Abstract][Full Text] [Related]
7. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267 [TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia. Yan Y; Tang L; Wang X; Zhou K; Hu F; Duan H; Liu X; Hua Y; Wang C Orphanet J Rare Dis; 2023 Dec; 18(1):380. PubMed ID: 38053087 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Roses-Noguer F; Jarman JW; Clague JR; Till J Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999 [TBL] [Abstract][Full Text] [Related]
10. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846 [TBL] [Abstract][Full Text] [Related]